Supplemental Digital Content 5. Distribution of reimbursed expenditures by categories of expenditure according to categories of health conditions and to health conditions from 3 categories with the highest expenditures in 2019

ambulatory care

hospital care cash benefits

## A. categories of health conditions

CVDs and chronic treatments	52%		40%	9%
Diabetes	84%			<mark>10%</mark> 7%
Cancers	41%		53%	6%
Psychiatric diseases and chronic treatments	29% 48		6	23%
Neurologic diseases	63%		29	% 8%
Chronic respiratory diseases (a)	62%		28%	<mark>6 10%</mark>
Chronic inflammatory diseases	61%		25%	14%
Rare diseases	74%			<mark>24% 2%</mark>
HIV infection	88%			<mark>8%</mark> 4%
End-stage renal disease	30%		68%	2%
Liver or pancreas diseases (a)	55%		36%	9%
Other long term diseases	75%			17% 9%
Maternity	15%	43%		43%
Hospitalisation for other reasons	14% 77%		0	9%
Analgesic or NSAI treatment (b)	52	% 8	8%	40%
Usual Care	91%			9%
No health condition identified	64%		10%	26%

## B. cardiovascular diseases and treatments

Acute coronary syndrome	
ronic coronary disease without acute event	Ch
Acute stroke	
Sequelae of stroke	
Acute heart failure	
Chronic heart failure without acute event	
Peripheral vascular diseases	
Heart arrhythmia or conduction disorders	
Valvular heart diseases	
Pulmonary embolism	
Other cardiovascular diseases	
Antihypertensive treatments (c)	
Lipid-lowering treatments (c)	

me	11%		83%		5%
ent		56%		34%	10%
oke	9%		89%		3%
oke		64%		23%	14%
ure	24%		769	%	
ent		83	%		13% 4%
ses		46%		47%	7%
ers		49%		48%	3%
ses	21%		76%		3%
sm	17%		78%		5%
ses	40	0%	5	52%	8%
(c)		76%		<mark>7%</mark>	16%
(c)		78%	)	<mark>7%</mark>	15%

## C. cancers

Active female breast cancer	41%		50%	9%
Follow-up for female breast cancer	65	%	<mark>11%</mark>	24%
Active colorectal cancer	27%	699	%	4%
Follow-up for colorectal cancer	6	9%	17%	14%
Active lung cancer	30%	67	7%	<mark>3%</mark>
Follow-up for lung cancer	55%	1	<mark>8%</mark> 2	27%
Active prostate cancer	65%		349	<mark>% 1</mark> %
Follow-up for prostate cancer		86%		<mark>11%3</mark> %
Other active cancers	37%		60%	<mark>4%</mark>
Follow-up for other cancers	649	%	15%	21%

## D. psychiatric diseases and treatments

Psychotic disorders	17%	77%	6%
Neurotic and mood disorders	22%	50%	27%
Mental impairment	32%		<mark>67% 1</mark> %
Addictive disorders	13%	70%	17%
Psychiatric disorders having begun in childhood	17% 83%		)
Other psychiatric disorders	21%	67%	12%
Antidepressant or mood-regulating treatments (c)	42%	9%	49%
Neuroleptic treatments (c)		62%	<mark>10%</mark> 29%
Anxiolytic treatments (c)	54	4% <mark>7%</mark>	39%
Hypnotic treatments (c)		62%	<mark>7%</mark> 32%

(a) excluding cystic fibrosis; (b) excluding diseases, other chronic treatments, maternity or hospitalisation; (c) without a specific diagnosis identified. Abbreviation: CVD, cardiovascular diseases; NSAI, non-steroidal anti-inflammatory